Tuberculosis and beta-lactam antibiotics.

Area of Science:

• Microbiology and Infectious Diseases
• Pharmacology and Drug Discovery

Background:

• Tuberculosis (TB) remains a significant global health challenge, complicated by rising multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains.
• The emergence of resistant TB necessitates the exploration of novel therapeutic strategies and the re-evaluation of existing antibiotic classes.

Purpose of the Study:

• To review current knowledge on beta-lactam antibiotics for treating tuberculosis.
• To discuss the potential of beta-lactamase inhibitors in combination therapy against Mycobacterium tuberculosis.
• To explore future perspectives for beta-lactam antibiotics in TB treatment regimens.

Main Methods:

• Literature review of existing studies on beta-lactam antibiotics and their efficacy against Mycobacterium tuberculosis.
• Analysis of in vitro and in vivo data regarding the effectiveness of beta-lactam antibiotics, particularly in combination with beta-lactamase inhibitors.

Main Results:

• Beta-lactam antibiotics function by inhibiting bacterial cell wall biosynthesis.
• The presence of beta-lactamase enzymes in TB bacilli poses a challenge to the efficacy of beta-lactam antibiotics.
• Combinations of beta-lactam antibiotics with beta-lactamase inhibitors have demonstrated effectiveness against Mycobacterium tuberculosis in both laboratory and clinical settings.

Conclusions:

• Beta-lactam antibiotics, when combined with beta-lactamase inhibitors, represent a promising therapeutic avenue for combating resistant tuberculosis strains.
• Further research and clinical trials are warranted to fully establish the role of these combinations in TB treatment protocols.
• This approach offers a potential strategy to overcome resistance mechanisms and improve TB treatment outcomes.